<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01724879</url>
  </required_header>
  <id_info>
    <org_study_id>GMALL-PH-01</org_study_id>
    <secondary_id>2010-022854-18</secondary_id>
    <nct_id>NCT01724879</nct_id>
  </id_info>
  <brief_title>Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)</brief_title>
  <official_title>Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard treatment approach for young patients with Positive Acute Lymphoblastic
      Leukemia (Ph+ALL) is the combination of a chemotherapy protocol employing four to five
      cytotoxic agents typically used for ALL together with imatinib. It is recommended to propose
      allogeneic Standard Induction and Consolidation Therapy (SCT) to all eligible patients with a
      suitable donor and to continue imatinib with or without additional therapy in patients not
      undergoing SCT.

      This protocol is a study for newly diagnosed Philadelphia chromosome positive acute
      lymphoblastic leukemia in patients aged 18 to 55 years.

      The objective of this strategy is to improve the overall results in the treatment of adult
      ALL with the addition of specific molecules to the common chemotherapeutic schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present study, the potent ABL tyrosine kinase inhibitor, Dasatinib will be added to
      standard induction and consolidation chemotherapy for the Philadelphia positive chromosome
      sub-group of ALL patients aged 18 to 55 years.

      The Study hypothesis is, that Dasatinib in combination with standard chemotherapy according
      to GMALL protocol 07/2003 is feasible and induces cytologic and molecular remission rates
      comparable to chemotherapy in combination with imatinib without increased treatment-related
      mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related discontinuation of study treatment (Proportion of Patients)</measure>
    <time_frame>Day 120</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular complete remission rate (CR)</measure>
    <time_frame>Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic complete remission rate</measure>
    <time_frame>Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade III and IV txicity by Common Terminology Criteria for Adverse Events Version 3</measure>
    <time_frame>Day 120</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Philadelphia Positive Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Dasatinib and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib, QD p.o. administration, day 1 to EOS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))</description>
    <arm_group_label>Dasatinib and chemotherapy</arm_group_label>
    <other_name>Sprycel (R)</other_name>
    <other_name>BMS-354825</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed new diagnosis of Philadelphia chromosome or BCR-ABL positive acute
             lymphoblastic leukemia

          -  Male or female patients aged 18-55 years

          -  Not previously treated except for prephase (corticosteroids, cyclophosphamide, single
             dose VCR will be permitted) therapy during establishment of the diagnosis

          -  Signed written inform consent, willingness and ability to comply with all study
             procedures

          -  Molecular detection of BCR-ABL transcripts

          -  Willingness of women of child-bearing potential (WOCBP) and male subjects whose sexual
             partners are WOCBP, to use an effective form of contraception (pearl index &lt; 1%), such
             as complete sexual abstinence, combined oral contraceptive, hormone IUCD, vaginal
             hormone ring, transdermal contraceptive patch, contraceptive implant or depot
             contraceptive injection in combination with a second method of contraception like a
             condom or a cervical cap / diaphragm with spermicide or surgical sterilisation
             (vasectomy) in male patients or male partners during the study and at least 6 months
             thereafter. WOCBP are defined as sexually mature women who have not undergone a
             hysterectomy or surgical sterilization or who have not been naturally postmenopausal
             for at least 12 consecutive months (i.e., who has had menses any time in the preceding
             12 consecutive months).

          -  Negative pregnancy test for women of child-bearing potential.

        Exclusion Criteria:

          -  Patients with ECOG status &gt; 2

          -  Patients with QTcF &gt; 470 ms

          -  Cardiac insufficiency NYHA grade III/IV, LEVF &lt; 50%, myocardial infarction within the
             past 6 months prior to study

          -  Active secondary malignancy requiring treatment

          -  Patients with active, uncontrolled bacterial, viral or fungal infection

          -  Known infection with HIV, Hepatitis B (except post vaccinal profile) or C

          -  Inadequate hepatic functions defined as ASAT or ALAT &gt; 2,5 times the institutional
             upper limit of normal and total bilirubin &gt; 2 fold the institutional upper limit
             unless considered to be due to organ involvement by the leukemia

          -  Concurrent severe diseases which exclude the administration of therapy

          -  Expected non-compliance or inability to understand informed consent

          -  Female patients who are pregnant or breast feeding

          -  Treatment with other investigational antileukemic agents after informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Gökbuget, Dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Frankfurt, Medical Dept. II</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Münster</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig, José-Carreras-Haus</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Poliklinik der Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uct-frankfurt.de/content/studien/studienregister/zu_den_studien/index_ger.html</url>
    <description>Trial register of University Cancer Center Frankfurt, additional trial information</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>November 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2012</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Nicola Goekbuget</investigator_full_name>
    <investigator_title>Dr. med., MD</investigator_title>
  </responsible_party>
  <keyword>philadelphia chromosome</keyword>
  <keyword>BCR-ABL</keyword>
  <keyword>ALL</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>dasatinib</keyword>
  <keyword>Sprycel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

